EXEL · Insider Trading
Exelixis Inc
Every open-market purchase and sale reported by EXEL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Mary C Beckerle | Director | Sell | −9,812 | −$526.51K |
| 2026-06-03 | Sue Gail Eckhardt | Director | Sell | −9,812 | −$491.97K |
| 2026-06-03 | Jack L Wyszomierski | Director | Sell | −3,925 | −$198.41K |
| 2026-05-29 | David Edward Johnson | Director | A | +38,266 deriv. | — |
| 2026-05-29 | George Poste | Director | A | +8,367 | — |
| 2026-05-29 | Jack L Wyszomierski | Director | A | +8,367 | — |
| 2026-05-29 | Bob Oliver | Director | A | +8,367 | — |
| 2026-05-29 | Mary C Beckerle | Director | A | +8,367 | — |
| 2026-05-29 | Maria C Freire | Director | A | +8,367 | — |
| 2026-05-29 | Julie Smith | Director | A | +8,367 | — |
| 2026-05-29 | Sue Gail Eckhardt | Director | A | +8,367 | — |
| 2026-05-29 | Tomas J. Heyman | Director | A | +8,367 | — |
| 2026-05-29 | Stelios Papadopoulos | Director | A | +8,367 | — |
| 2026-05-28 | Dana Aftab | EVP, Research and Development | Sell | −43,451 | −$2.19M |
| 2026-05-22 | Patrick J. Haley | EVP, Commercial | Sell | −32,110 | −$1.60M |
| 2026-05-19 | Dana Aftab | EVP, Research and Development | F | −30,578 | −$1.56M |
| 2026-05-19 | Brenda Hefti | SVP and General Counsel | MIXED | −13,036 | −$660.24K |
| 2026-05-19 | Patrick J. Haley | EVP, Commercial | F | −33,265 | −$1.70M |
| 2026-05-19 | Christopher J. Senner | EVP and CFO | MIXED | −75,793 | −$3.83M |
| 2026-05-19 | Michael Morrissey | President and CEO | MIXED | −128,497 | −$6.57M |
| 2026-05-08 | Michael Morrissey | President and CEO | G | −109,676 | — |
| 2026-05-08 | George Poste | Director | Sell | −60,000 | −$2.74M |
| 2026-05-08 | Maria C Freire | Director | MIXED | — | −$541.23K |
| 2026-05-08 | Mary C Beckerle | Director | MIXED | −3,856 | −$284.03K |
| 2026-03-02 | Michael Morrissey | President and CEO | MIXED | +60,159 | — |
| 2026-03-02 | Patrick J. Haley | EVP, Commercial | A | +40,459 | — |
| 2026-03-02 | Brenda Hefti | SVP and General Counsel | A | +23,119 | — |
| 2026-03-02 | Christopher J. Senner | EVP and CFO | A | +52,018 | — |
| 2026-03-02 | Dana Aftab | EVP, Research and Development | A | +52,018 | — |
| 2026-02-26 | Dana Aftab | EVP, Research and Development | Sell | −47,918 | −$2.13M |
| 2026-02-23 | Dana Aftab | EVP, Research and Development | Sell | −29,873 | −$1.32M |
| 2026-02-20 | Jack L Wyszomierski | Director | MIXED | −78,940 | −$3.97M |
| 2026-02-19 | Julie Smith | Director | MIXED | — | −$2.63M |
| 2026-02-18 | Brenda Hefti | SVP and General Counsel | MIXED | −24,099 | −$1.06M |
| 2026-02-18 | Bob Oliver | Director | MIXED | −21,162 | −$1.15M |
| 2026-02-18 | Dana Aftab | EVP, Research and Development | F | −39,205 | −$1.72M |
| 2026-02-18 | Sue Gail Eckhardt | Director | Sell | −3,856 | −$168.85K |
| 2026-02-18 | Michael Morrissey | President and CEO | MIXED | +4,704 | −$10.98M |
| 2026-02-18 | Patrick J. Haley | EVP, Commercial | MIXED | −99,297 | −$4.33M |
| 2026-02-18 | Christopher J. Senner | EVP and CFO | MIXED | −100,765 | −$4.39M |
| 2026-01-16 | Christopher J. Senner | EVP and CFO | MIXED | +109,015 | −$1.83M |
| 2026-01-16 | Patrick J. Haley | EVP, Commercial | MIXED | +107,176 | −$1.46M |
| 2026-01-16 | Dana Aftab | EVP, Research and Development | MIXED | +92,324 | −$1.23M |
| 2026-01-16 | Michael Morrissey | President and CEO | MIXED | +408,549 | −$6.31M |
| 2025-12-05 | Brenda Hefti | SVP and General Counsel | A | +30,170 | — |
| 2025-11-26 | David Edward Johnson | Director | Buy | +55,064 | +$2.37M |
| 2025-11-24 | Dana Aftab | EVP, Research and Development | G | −24,000 | — |
| 2025-11-24 | Patrick J. Haley | EVP, Commercial | Sell | −72,230 | −$3.05M |
| 2025-11-19 | Bob Oliver | Director | G | −1,044 | — |
| 2025-11-13 | Mary C Beckerle | Director | MIXED | −18,838 | −$897.99K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael Morrissey | President and CEO | 3,366,335 | $217.40M |
| David Edward Johnson | Director | 1,571,438 | $101.48M |
| Stelios Papadopoulos | Director | 1,197,595 | $77.34M |
| Christopher J. Senner | EVP and CFO | 989,941 | $63.93M |
| Caligan Partners LP | Director | 928,906 | $59.99M |
| Jeffrey Hessekiel | EVP & General Counsel | 719,395 | $46.46M |
| Dana Aftab | EVP, Research and Development | 600,576 | $38.79M |
| Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | 538,169 | $34.75M |
| Patrick J. Haley | EVP, Commercial | 357,638 | $23.10M |
| Jack L Wyszomierski | Director | 284,384 | $18.37M |
| George Poste | Director | 127,199 | $8.21M |
| Brenda Hefti | SVP and General Counsel | 118,914 | $7.68M |
| Maria C Freire | Director | 109,186 | $7.05M |
| Tomas J. Heyman | Director | 50,649 | $3.27M |
| Bob Oliver | Director | 29,487 | $1.90M |
| Julie Smith | Director | 28,957 | $1.87M |
| Sue Gail Eckhardt | Director | 16,079 | $1.04M |
| Mary C Beckerle | Director | 16,079 | $1.04M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EXEL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.